Search Result

Results for "

PPAR Agonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PPAR (227) Adiponectin Receptor (1) Akt (1) Aldose Reductase (1) AMPK (1) Amyloid-β (2) Angiotensin Receptor (3) Antibiotic (4) Apoptosis (13) Autophagy (26) Bacterial (9) Biochemical Assay Reagents (1) Bombesin Receptor (1) Calcium Channel (1) Cannabinoid Receptor (2) COX (1) Cytochrome P450 (8) Drug Metabolite (3) EGFR (1) Endogenous Metabolite (19) ERK (1) Estrogen Receptor/ERR (1) Ferroptosis (16) Free Fatty Acid Receptor (5) Fungal (3) Glucocorticoid Receptor (1) Glucosidase (2) HIF/HIF Prolyl-Hydroxylase (3) IKK (1) Influenza Virus (1) Isotope-Labeled Compounds (18) Keap1-Nrf2 (3) Leukotriene Receptor (1) Liposome (1) LXR (2) NF-κB (10) Nuclear Hormone Receptor 4A/NR4A (1) Organoid (1) PAK (8) PARP (1) PGC-1α (1) Phosphatase (2) PI3K (1) Potassium Channel (1) Prostaglandin Receptor (2) RAR/RXR (10) Reactive Oxygen Species (2) Sirtuin (1) Stearoyl-CoA Desaturase (SCD) (1) STING (1) TNF Receptor (1) TRP Channel (6)
By Research Areas:	Cancer (72) Cardiovascular Disease (37) Endocrinology (5) Infection (5) Inflammation/Immunology (62) Metabolic Disease (154) Neurological Disease (28)
Oligonucleotides:	Phospholipids (1)

250

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: PPAR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-U00340

PPAR agonist 1	PPAR	Metabolic Disease
PPAR agonist 1 is an agonist of PPAR α and PPAR γ, used for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight.

HY-N0234

Bavachinin 3 Publications Verification 7-O-Methylbavachin; Bavachinin A	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology Cancer
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-163547

PPAR agonist 5	PPAR	Inflammation/Immunology
PPAR agonist 5 (compound 4b) is a potent *PPAR* agonist with EC₅₀ values of 3.20, 1.51, 1.92 µM for PPARα, PPARβ/δ, PPARγ, respectively. PPAR agonist 5 shows anti-inflammatory effect .

HY-163443

PPAR agonist 4	PPAR	Others
PPAR agonist 4 (Compound 12) is an orally active agonist for peroxisome proliferator-activated receptor (PPAR), which activates PPARα, PPARδ and PPARγ with EC₅₀s of 0.7, 0.7 and 1.8 μM, respectively. PPAR agonist 4 exhibits anti-liver fibrosis efficacy .

HY-160003

PPARγ agonist 9	PPAR	Metabolic Disease
PPARγ agonist 9 is an agonist of PPARγ. PPARγ agonist 9 is the analogue of lysophosphatidic acid with an EC₅₀ more than 10 μM for LPA₃ receptor .

HY-107333

Cinoxate	PPAR	Metabolic Disease
Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with K_i value of 18.0 μM. Cinoxate can be used to study obesity .

HY-N0234R

Bavachinin (Standard)	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase	Inflammation/Immunology
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-148922

PPARα/γ agonist 2	PPAR	Metabolic Disease
PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC₅₀ values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent .

HY-139177

PPARα agonist 2	PPAR	Cardiovascular Disease
PPARα agonist 2 (compound 4u) is a potent and selective PPARα agonist with an EC₅₀ of 37 nM. PPARα agonist 2 exhibits >2,700-fold selectivity for PPARα over other PPAR isoforms. PPARα agonist 2 has the potential for retinal disorders research .

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-162123

PPARα/δ agonist 2	PPAR	Inflammation/Immunology
PPARα/γ agonist 4 (compound 14) is a potent PPARα and PPARδ agonist with EC₅₀s of 3255 nM and 1475 nM for human PPARα and PPARβ/δ, respectively. PPARα/γ agonist 4 shows anti-inflammatory effects .

HY-146480

PPARγ agonist 5	PPAR	Cancer
PPARγ agonist 5 (Compound 1) is a potent and selective agonist of PPARγ. PPARγ agonist 5 has the potential for the research of cancer diseases .

HY-146482

PPARγ agonist 6	PPAR	Cancer
PPARγ agonist 6 (Compound 12) is a potent and selective agonist of PPARγ. PPARγ agonist 6 has the potential for the research of cancer diseases .

HY-146438

PPARγ agonist 3	PPAR	Cancer
PPARγ agonist 3 (Compound 18a) is a potent and selective agonist of PPARγ. PPARγ agonist 3 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 3 exerts antitumor potency only in combination with Imatinib .

HY-146439

PPARγ agonist 4	PPAR	Cancer
PPARγ agonist 4 (Compound 18b) is a potent and selective agonist of PPARγ. PPARγ agonist 4 is not cytotoxic neither on non-resistant nor on resistant cells. PPARγ agonist 4 exerts antitumor potency only in combination with Imatinib .

HY-147511

PPARγ agonist 7	PPAR	Others
PPARγ agonist 7 (Compound 3a) is a potent and selective agonist of PPARγ. PPARγ agonist 7 promotes adiponectin production in human bone marrow mesenchymal stem cells (hBM-MSCs) as a novel PPARγ full agonist (EC₅₀, 4.34 μM) .

HY-153982

PPARγ agonist 8	PPAR	Metabolic Disease
PPARγ agonist 8 is an agonist of PPARγ. PPARγ agonist 8 induces peroxisome proliferator response element (PPRE)-luciferase activity with an EC₅₀ of 0.2 μM .

HY-143239

PPARα/γ agonist 1	PPAR	Metabolic Disease
PPARα/γ agonist 1 (compound 5b) is a potent and dual PPARα/γ partial agonist with EC₅₀ values of 28 nM and 69 nM for PPARα and PPARγ, respectively. PPARα/γ agonist 1 is a promising prototype for dyslipidemia and diabetes research .

HY-162320

PPARγ agonist 12	PPAR	Metabolic Disease
PPARγ agonist 12 (compound 9i) is a potent and selective PPARγ agonist with EC₅₀s of 3.98 and 15.42 μM against PPARγ and PPARδ, respectively. PPARγ agonist 12 improves insulin secretion and has anti-diabetic effect .

HY-146731

PPARγ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders .

HY-100120

Pparδ agonist 2	PPAR	Metabolic Disease
Pparδ agonist 2 is a PPARδ agonist extracted from patent WO 2016057656 A1.

HY-121542

PPARδ agonist 10	PPAR	Metabolic Disease
PPARδ agonist 10 (compound 7) is an orally active, selective, and partial agonist of PPARδ, with EC₅₀ values of 0.053 μM and 0.30 µM for hPPARδ(LBD)-GAL4 and mPPARδ, respectively. PPARδ agonist 10 is a partial PPARδ agonist in transactivation assay but a full agonist on free fatty acids (FFA) oxidation in muscle cells both in vitro and in vivo. PPARδ agonist 10 can be used for dyslipidemia research .

HY-159146

PPARα agonist 4	PPAR STING Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
PPARα agonist 4 (compound BH400) is a PPARα agonist (EC₅₀= 1.2 μM). PPARα agonist 4 also inhibits STING (IC₅₀: 8.1 μM). PPARα agonist 4 reduces the CoCl₂-induced production of ROS and LPS-induced secretion of IL-6. The PPARα agonist 4 restores the decreased expression of PCG1α induced by LPS .

HY-14817

Indeglitazar PPM 204	PPAR	Metabolic Disease
Indeglitazar (PPM 204) is an orally available *PPAR* pan-agonist for all three PPARα, PPARδ and PPARγ .

HY-120596

PPARδ/γ agonist 1 sodium	PPAR	Neurological Disease
PPARδ/γ agonist 1 sodium is a chemically unique and brain penetrant dual PPAR delta/gamma agonist. PPARδ/γ agonist 1 sodium can be used for the research of Alzheimer’s disease .

HY-163862

PPARα agonist 3	PPAR Reactive Oxygen Species	Inflammation/Immunology
PPARα agonist 3 (Compound A229) is a PPARα agonist (EC₅₀: 590 nM). PPARα agonist 3 inhibits TBHP or 4-HNE (HY-113466)-induced production of ROS .

HY-146742

PPARγ agonist 2	PPAR	Metabolic Disease
PPARγ agonist 2 is a potent PPARγ partial agonist and can be used for metabolic disease research .

HY-116468

PPARγ agonist 11	PPAR	Metabolic Disease
PPARγ agonist 11 (compound 20) is a selective agonist of PPARγ (EC₅₀: 0.1 μM) .

HY-107901

Pparδ agonist 1	PPAR	Cardiovascular Disease Metabolic Disease
Pparδ agonist 1 is a *PPAR-δ* agonist, with an EC₅₀ of 5.06 nM, used in the research of PPAR-delta related diseases, such as mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases.

HY-100428

Netoglitazone MCC-555; Isaglitazone	PPAR	Metabolic Disease
Netoglitazone is a dual agonist of PPARα and PPARγ with antihyperglycemic activity .

HY-B0287

Clofibrate 2 Publications Verification	PPAR	Metabolic Disease
Clofibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPAR*γ, respectively.

HY-162578

PPARα/γ agonist 4	PPAR	Metabolic Disease
PPARα/γ agonist 4 (Compound (S)-7) is an orally active dual potent agonist of PPARα and PPARγ, with EC₅₀ values of 0.061 μM and 1.42 μM respectively. PPARα/γ agonist 4 acts through an insulin-independent mechanism and exhibits mitochondrial pyruvate carrier inhibition and anti-diabetic properties. PPARα/γ agonist 4 is expected to be used in research for dyslipidemic type 2 diabetes .

HY-141494

Pparδ agonist 5	PPAR	Metabolic Disease
Pparδ agonist 5, an orally active PPARδ-selective agonist (EC₅₀=0.335 μM), is much greater than that of the prototypical standard GW0742. Pparδ agonist 5 promotes improvements in bone density and microarchitecture in vivo .

HY-159944

PPARγ agonist 14	PPAR	Neurological Disease Metabolic Disease Inflammation/Immunology
PPARγ agonist 14 (compound 3) is a PPARy agonist (EC₅₀=2.4 μM) with anti-diabetic activity. PPARγ agonist 14 can improve intracellular glucose uptake, promote insulin release, and lower blood sugar. In addition, PPARγ agonist 14 also improves mitochondrial function, reduces oxidative stress, and inhibits inflammatory factors. PPARγ agonist 14 can be used in the study of neurodegenerative diseases, neuroinflammatory diseases, and other diseases .

HY-13928

GW0742 10+ Cited Publications GW610742	PPAR	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
GW0742 is a potent PPARβ and PPARδ agonist, with an IC₅₀ of 1 nM for human PPARδ in binding assay, and EC₅₀s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

HY-20019

L-165041	PPAR	Metabolic Disease
L-165041 is a cell permeable PPARδ agonist, with K_is of 6 nM and appr 730 nM for PPARδ and PPARγ, respectively, and induces adipocyte differentiation in NIH-PPARδ cells.

HY-13861

GW7647 15+ Cited Publications	PPAR	Cardiovascular Disease
GW7647 is a potent PPARα agonist, with EC₅₀s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-162963

PPARδ agonist 11	PPAR	Inflammation/Immunology
PPARδ agonist 11 (Compound 11) is a selective agonist for PPARδ with an EC₅₀ of 20 nM. PPARδ agonist 11 reduces the levels of nitrite oxide (NO), proinflammatory cytokines TNFα and IL-6 in LPS (HY-D1056)-stimulated RAW264.7 cell, and exhibits anti-inflammatory efficacy via NF-κB pathway. PPARδ agonist 11 exhibits good stability in human liver microsomes and plasma. PPARδ agonist 11 ameliorates Carrageenan (HY-125474)-induced foot edema .

HY-149429

PPARδ agonist 9	PPAR	Metabolic Disease
PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC₅₀: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%) .

HY-163294

PPARγ agonist 10	PPAR	Metabolic Disease
PPARγ agonist 10 (compound 33g) is a PPARγ agonist, and stimulats the insulin secretion, glucose uptake and insulin Sensitivity in βTC6 Cells .

HY-167950

PPARα/γ agonist 5	Others	Metabolic Disease
PPARα/γ agonist 5 is a dual PPARα/γ agonist with significant biological activity exhibited at low concentrations. The EC₅₀ of PPARα/γ agonist 5 are 0.358μM and 1.21μM respectively, showing its potential in inhibiting type 2 diabetes and lipid metabolism disorders. PPARα/γ agonist 5 was selected for clinical development due to its high efficacy .

HY-16086

Balaglitazone 1 Publications Verification DRF 2593; NN 2344	PPAR	Metabolic Disease
Balaglitazone is a selective partial PPARγ agonist with an EC₅₀ of 1.351 μM for human PPARγ.

HY-N9333

Wistin	PPAR	Metabolic Disease Cancer
Wistin, isolated from Caragana sinica roots, is a PPARα and PPARγ agonist .

HY-10678

BMS-687453 2 Publications Verification	PPAR	Cardiovascular Disease
BMS-687453 is a potent and selective PPARα agonist, with an EC₅₀ and IC₅₀ of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.

HY-106266

Chiglitazar Carfloglitazar	PPAR	Metabolic Disease
Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.

HY-B0637

Bezafibrate 5+ Cited Publications BM15075	PPAR	Cardiovascular Disease Metabolic Disease
Bezafibrate is an agonist of *PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPAR*δ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-143862

Pparδ agonist 7	PPAR	Metabolic Disease
Pparδ agonist 7 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 7 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2019105234A1, compound TM4) .

HY-143863

PPARδ agonist 8	PPAR	Metabolic Disease
Pparδ agonist 8 is a potent agonist of Pparδ. The peroxisome proliferator-activated receptor (PPAR) is a member of the intranuclear receptor transcription factor superfamily that plays a key role in the regulation of metabolic homeostasis, inflammation, cell growth and differentiation in vivo. Pparδ agonist 8 has the potential for the research of non-alcoholic fatty liver disease (NAFLD) (extracted from patent WO2021169769A1, compound TM2) .

HY-16995

Pirinixic acid 15+ Cited Publications Wy-14643	PPAR	Metabolic Disease Inflammation/Immunology
Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC₅₀s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.

HY-B0287S

Clofibrate-d4	PPAR	Metabolic Disease
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

Cat. No.	Product Name	Type

HY-17356G

Fenofibrate (GMP)

Fluorescent Dye

Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Cat. No.	Product Name	Type

HY-107737

1,2-DLPC 1 Publications Verification 1,2-Dilauroyl-sn-glycero-3-phosphocholine	Drug Delivery
1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breakdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells .

HY-17356G

Fenofibrate (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0234

Bavachinin 3 Publications Verification 7-O-Methylbavachin; Bavachinin A	Structural Classification Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-107542

Oleoylethanolamide 1 Publications Verification N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide	Cardiovascular Disease Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite PPAR
Oleoylethanolamide is a high affinity endogenous *PPAR-α* agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-N6869

Dehydroabietic acid	Infection Structural Classification Microorganisms other families Classification of Application Fields Anti-aging Terpenoids Source classification Diterpenoids Plants Inflammation/Immunology Disease Research Fields	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual *PPAR-α/γ* agonist and *PPAR-γ* partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N2025

Oroxin A	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Metabolic Disease Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz Disease Research Fields	PPAR Glucosidase
Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-N0783

Eupatilin 5+ Cited Publications	Structural Classification Flavonoids Neurological Disease Classification of Application Fields Flavones Plants Compositae Disease Research Fields Sindora sumatrana Miq. Cancer	PPAR Autophagy
Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi, is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.

HY-N0234R

Bavachinin (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N9333

Wistin	Flavonoids other families Classification of Application Fields Source classification Metabolic Disease Plants Disease Research Fields Isoflavones	PPAR
Wistin, isolated from Caragana sinica roots, is a PPARα and PPARγ agonist .

HY-13956R

Pioglitazone (Standard)	Human Gut Microbiota Metabolites Source classification Endogenous metabolite	PPAR Ferroptosis
Pioglitazone (Standard) is the analytical standard of Pioglitazone. This product is intended for research and analytical applications. Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC₅₀ of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .

HY-N6869R

Dehydroabietic acid (Standard)	Structural Classification Microorganisms other families Terpenoids Source classification Diterpenoids Plants	Antibiotic PPAR Bacterial Fungal
Dehydroabietic acid (Standard) is the analytical standard of Dehydroabietic acid. This product is intended for research and analytical applications. Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice .

HY-N2025R

Oroxin A (Standard)	Structural Classification Flavonoids Flavones Source classification Bignoniaceae Plants Oroxylum indicum (Linn.) Bentham ex Kurz	PPAR Glucosidase
Oroxin A (Standard) is the analytical standard of Oroxin A. This product is intended for research and analytical applications. Oroxin A is the major component of an ethanol-water Oroxylum indicum (L.) Kurz (Bignoniaceae) seed extract (OISE). Oroxin A acts as a partial PPARγ agonist that can activate PPARγ transcriptional activation. Oroxin A activates PPARγ by docking into the PPARγ protein ligand-binding domain. Oroxin A also exhibits an inhibitory activity against α-glucosidase and an antioxidant capacity . Oroxin A exerts anti-breast cancer effects by inducing ER stress-mediated senescence .

HY-U00450

4-O-Methyl honokiol	Structural Classification Classification of Application Fields Source classification Lignans Plants Monophenols other families Magnolia officinalis. Rehd. et Wils. Magnoliaceae Phenols Phenylpropanoids Inflammation/Immunology Disease Research Fields Cancer	PPAR NF-κB
4-O-Methyl honokiol is a natural neolignan isolated from Magnolia officinalis, acts as a PPARγ agonist, and inhibtis NF-κB activity, used for cancer and inflammation research.

HY-N0246

Saikosaponin A 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Umbelliferae Plants Disease Research Fields Carphephorus corymbosus (Nutt.) Torr. & A.Gray Cancer	LXR Bacterial
Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also serve as a potential peroxisome proliferator-activated receptor γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-N7624

Methyl oleanonate 3-Oxoolean-12-en-28-oic acid methyl ester	Triterpenes Pistacia lentiscus var. Chia other families Classification of Application Fields Terpenoids Source classification Plants Disease Research Fields Cancer Anacardiaceae	PPAR
Methyl oleanonate is a natural triterpene PPARγ agonist isolated from the species of Pistacia lentiscus var. Chia . Methyl oleanonate is a modified oleanolic acid derivative with anti-cancer effects .

HY-W341997

9-Octadecynoic acid	Structural Classification Leguminosae Paramacrolobium coeruleum (Taub.) J.Léonard Ketones, Aldehydes, Acids Source classification Plants	PPAR
9-Octadecynoic acid is a DNA binding agent with a dissociation constant of 1.8 mM. 9-Octadecynoic acid is also an agonist for peroxisome proliferator-activated receptor γ (PPARγ) .

HY-N0163

Magnolol 4 Publications Verification	Cardiovascular Disease Structural Classification Neurological Disease Classification of Application Fields Source classification Lignans Plants Magnolia officinalis. Rehd. et Wils. Magnoliaceae Phenols Polyphenols Phenylpropanoids Inflammation/Immunology Disease Research Fields	RAR/RXR PPAR Autophagy Bacterial
Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC₅₀ values of 10.4 µM and 17.7 µM, respectively.

HY-113631

Amorfrutin B	Structural Classification Monophenols Leguminosae Source classification Phenols Amorpha fruticosaL. Plants	PPAR
Amorfrutin B is a highly potent natural peroxisome proliferation-activated receptor γ (PPARγ) agonist with oral activity with K_i values of 19 nM and EC₅₀ values of 73 nM, respectively. Amorfrutin B has hypoglycemic and neuroprotective activities .

HY-N0246R

Saikosaponin A (Standard)	Triterpenes Structural Classification Terpenoids Source classification Umbelliferae Plants Carphephorus corymbosus (Nutt.) Torr. & A.Gray	LXR Bacterial
Saikosaponin A (Standard) is the analytical standard of Saikosaponin A. This product is intended for research and analytical applications. Saikosaponin A is the main active ingredient in Bupleurum chinense, which can regulate lipid metabolism and promote cholesterol efflux in early atherosclerosis. In addition, Saikosaponin A may also act as a potential peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist, significantly promoting the expression of *PPAR-γ*. Saikosaponin A can be used in the study of hyperlipidemic pancreatitis .

HY-15027

5-Aminosalicylic Acid 15+ Cited Publications Mesalamine; 5-ASA; Mesalazine	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields Cancer	PPAR PAK NF-κB Endogenous Metabolite
5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-N7687

Caulophyllogenin	Triterpenes Classification of Application Fields Leguminosae Terpenoids Source classification Acacia catechu (Linn. f.) Willd. Plants Disease Research Fields Inflammation/Immunology	PPAR
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC₅₀ of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation .

HY-N0783R

Eupatilin (Standard)	Structural Classification Flavonoids Neurological Disease Classification of Application Fields Source classification Plants Compositae Disease Research Fields Sindora sumatrana Miq. Cancer	PPAR Autophagy
Eupatilin (Standard) is the analytical standard of Eupatilin. This product is intended for research and analytical applications. Eupatilin, a lipophilic flavonoid isolated from Artemisia argyi Lévl. et Van., is a PPARα agonist, and possesses anti-apoptotic, anti-oxidative and anti-inflammatory activities.

HY-N6642

Ankaflavin	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Plants Inflammation/Immunology Disease Research Fields	PPAR Apoptosis
Ankaflavin, isolated from Monascus-Fermented red rice, is an orally active PPARγ agonist. Ankaflavin exhibits selective cytotoxic effect and induces cell death through apoptosis on cancer cells. Ankaflavin has anti-inflammatory, anti-cancer, antiatherosclerotic, and hypolipidemic effects .

HY-N0163R

Magnolol (Standard)	Structural Classification Magnolia officinalis. Rehd. et Wils. Magnoliaceae Source classification Lignans Phenols Polyphenols Phenylpropanoids Plants	RAR/RXR PPAR Autophagy Bacterial
Magnolol (Standard) is the analytical standard of Magnolol. This product is intended for research and analytical applications. Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 μM and 17.7 μM, respectively.

HY-N6641

Monascin	Structural Classification Natural Products Microorganisms other families Classification of Application Fields Source classification Pigments Plants Inflammation/Immunology Disease Research Fields Food Research	Keap1-Nrf2 PPAR
Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and PPARγ agonist .

HY-108568

15-Deoxy-Δ-12,14-prostaglandin J2 1 Publications Verification 15d-PGJ2; 15-Deoxy-Δ12,14-PGJ2	Structural Classification Neurological Disease Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Inflammation/Immunology Disease Research Fields	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

HY-N9768

(10E,12E)-9-Oxo-10,12-octadecadienoic acid 9-oxo-ODA	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source classification	Fungal PPAR
(10E,12E)-9-Oxo-10,12-octadecadienoic acid (9-oxo-ODA) is a PPARα agonist that can be isolated from the basidiomycete Gomphus floccosus. (10E,12E)-9-Oxo-10,12-octadecadienoic acid enhances fatty acid oxidation through PPARα activation, thereby inhibiting triglyceride accumulation. (10E,12E)-9-Oxo-10,12-octadecadienoic acid also has antifungal (Fungal) activity .

HY-14649

Retinoic acid Maximum Cited Publications 61 Publications Verification Vitamin A acid; all-trans-Retinoic acid; ATRA	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Whitening Agent Cosmetic Research Endogenous metabolite Disease Research Fields Cancer	Organoid RAR/RXR PPAR Endogenous Metabolite Autophagy
Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC₅₀s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with K_d of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.

HY-15027R

5-Aminosalicylic Acid (Standard)	Structural Classification Monophenols Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite	PPAR PAK NF-κB Endogenous Metabolite
5-Aminosalicylic Acid (Standard) is the analytical standard of 5-Aminosalicylic Acid. This product is intended for research and analytical applications. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB. 5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-N6641R

Monascin (Standard)	Structural Classification Natural Products Microorganisms other families Source classification Plants	Keap1-Nrf2 PPAR
Monascin (Standard) is the analytical standard of Monascin. This product is intended for research and analytical applications. Monascin is a kind of azaphilonoid pigments extracted from Monascus pilosus-fermented rice (red-mold rice). Monascin also exhibits anti-tumor-initiating activity and anti-inflammatory activity with oral administration. Monascin inhibits the activation of NOR 1 (an NO donor). Monascin is a Nrf2 activator and PPARγ agonist .

HY-N10361

Drupanin	Monophenols Animals Classification of Application Fields Source classification Phenols Disease Research Fields Cancer	RAR/RXR PPAR Aldose Reductase
Drupanin is an orally active and selective AKR1C3 enzyme inhibitor and an RXRα agonist with an EC₅₀ value of 4.8 μM, which is found in green propolis. Drupanin also activates PPARγ moderately. Drupanin induces adipogenesis and elevates aP2 mRNA levels in 3T3-L1 fibroblasts Drupanin has the potential for the research of breast and prostate cancers .

HY-14649R

Retinoic acid (Standard) Maximum Cited Publications 61 Publications Verification Vitamin A acid (Standard); all-trans-Retinoic acid (Standard); ATRA (Standard)	Structural Classification Classification of Application Fields Ketones, Aldehydes, Acids Source classification Endogenous metabolite Disease Research Fields Cancer	RAR/RXR PPAR Endogenous Metabolite Autophagy
Retinoic acid (Standard) is the analytical standard of Retinoic acid. This product is intended for research and analytical applications. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC₅₀s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with K_d of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.

HY-108568R

15-Deoxy-Δ-12,14-prostaglandin J2 (Standard)	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	PPAR Endogenous Metabolite
15-Deoxy-Δ-12,14-prostaglandin J2 (Standard) is the analytical standard of 15-Deoxy-Δ-12,14-prostaglandin J2. This product is intended for research and analytical applications. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC₅₀ of 2 μM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC₅₀ of 7 μM .

Cat. No.	Product Name	Chemical Structure

HY-B0637S

Bezafibrate-d6
Bezafibrate-d₆ is the deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-13956S

Pioglitazone-d4
Pioglitazone-d₄ is a deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1].

HY-13956S1

Pioglitazone-d4 (alkyl)
Pioglitazone-d₄ (alkyl) (U 72107-d4 (alkyl)) is the deuterium labeled Pioglitazone. Pioglitazone (U 72107) is a potent and selective PPARγ agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively[1][2].

HY-B0287S

Clofibrate-d4
Clofibrate-d₄ is the deuterium labeled Clofibrate. Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ∼500 μM for murine PPARα and PPARγ, and 55 μM, ∼500 μM for human PPARα and PPARγ, respectively.

HY-B0637S1

Bezafibrate-d4
Bezafibrate-d₄ is deuterium labeled Bezafibrate. Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

HY-50935S

Troglitazone-d4
Troglitazone-d₄ is deuterium labeled Troglitazone. Troglitazone is a PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

HY-19937S1

Saroglitazar-d4
Saroglitazar-d₄ is the deuterium-labeled Saroglitazar (HY-19937). Saroglitazar-d₄ is a novel peroxisome proliferator-activated receptor (PPAR) agonist with predominant PPARα and moderate PPARγ activity with EC₅₀ values of 0.65 pM and 3 nM in HepG2 cells, respectively.

HY-17386S

Rosiglitazone-d3
Rosiglitazone-d₃ is the deuterium labeled Rosiglitazone. Rosiglitazone (BRL 49653) is a selective, orally active PPARγ agonist with EC50s of 30 nM, 100 nM and 60 nM for PPARγ1, PPARγ2, and PPARγ, respectively. Rosiglitazone binds to PPARγ with a Kd of approximately 40 nM. Rosiglitazone is also an activator of TRPC5 (EC50=~30 μM) and an inhibitor of TRPM3[1][2][3][4].

HY-N6807S

Elemicin-d3
Elemicin-d₃ is deuterated labeled Pemafibrate (HY-17618). Pemafibrate is a highly selective PPARα agonist, with an EC₅₀ of 1 nM.

HY-107542S2

Oleoylethanolamide-d2
Oleoylethanolamide-d₂ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-107542S

Oleoylethanolamide-d4
Oleoylethanolamide-d₄ is the deuterium labeled Oleoylethanolamide. Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

HY-117727S

Leriglitazone-d4

Leriglitazone-d₄ (MIN-102-d₄; Hydroxypioglitazone-d₄) is deuterium labeled Leriglitazone. Leriglitazone (Hydroxypioglitazone), a metabolite of pioglitazone.Leriglitazone (Hydroxypioglitazone) PioOH is a PPARγ agonist, stabilizes the PPARγ activation function-2 (AF-2) co-activator binding surface and enhances co-activator binding, affording slightly better transcriptional efficacy.Leriglitazone (Hydroxypioglitazone) binds to the PPARγ C-terminal ligand-binding domain (LBD) with Ki of 1.2 μM，induces transcriptional efficacy of the PPARγ (LBD) with EC50 of 680 nM .

HY-B1415S

Clofibric acid-d4
Clofibric acid-d₄ is the deuterium labeled Clofibric acid. Clofibric acid (Chlorofibrinic acid), the pharmaceutically active metabolite of lipid regulators Clofibrate, Etofibrate and Etofyllinclofibrate, is a PPARα agonist which exhibits hypolipidemic effects. Clofibric acid also is an herbicide[1][2][3].

HY-15027S

5-Aminosalicylic Acid-d3 hydrochloride
5-Aminosalicylic Acid-d₃ (hydrochloride) is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) hydrochloride acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.

HY-15027S1

5-Aminosalicylic acid-d3
5-Aminosalicylic acid-d₃ is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[1][2][3][4].

HY-15027S2

5-Aminosalicylic acid-13C6
5-Aminosalicylic acid- ¹³C₆ is the ¹³C labeled 5-Aminosalicylic Acid[1]. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[2][3][4].

HY-17386S1

Rosiglitazone-d4
Rosiglitazone-d₄ is deuterated labeled Rosiglitazone (HY-17386). Rosiglitazone (BRL 49653) is an orally active selective PPARγ agonist (EC₅₀: 60 nM, K_d: 40 nM). Rosiglitazone is an TRPC5 activator (EC₅₀: 30 μM) and TRPM3 inhibitor. Rosiglitazone can be used in the research of obesity and diabetes, senescence, ovarian cancer .

HY-15027S3

5-Aminosalicylic acid-d3 disodium
5-Aminosalicylic acid-d₃ disodium is deuterated labeled 5-Aminosalicylic Acid (HY-15027). 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB.5-Aminosalicylic acid can inhibit the activity of osteopontin (OPN).

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-14649S2

11-cis-Retinoic Acid-d5

11-cis-Retinoic Acid-d₅ is the deuterium labeled Retinoic acid. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha[1][2].

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].

HY-14649S4

Retinoic acid-d5

Retinoic acid-d₅ is the the deuterium labeled Retinoic acid (HY-14649). Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC₅₀s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with K_d of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha .

HY-17356S2

Fenofibrate-13C6
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-108568S

15-Deoxy-Δ-12,14-prostaglandin J2-d4

15-Deoxy-Δ-12,14-prostaglandin J2-d₄ is the deuterium labeled 15-Deoxy-Δ-12,14-prostaglandin J2. 15-Deoxy-Δ-12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin and a metabolite of PGD2. 15-Deoxy-Δ-12,14-prostaglandin J2 is a selective PPARγ (EC50 of 2 µM) and a covalent PPARδ agonist. 15-Deoxy-Δ-12,14-prostaglandin J2 promotes efficient differentiation of C3H10T1/2 fibroblasts to adipocytes with an EC50 of 7 μM[1][2].

HY-14649S3

Retinoic acid-d6

Retinoic acid-d₆ is the deuterium labeled Retinoic acid[1]. Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC50s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha[2][3][4][5][6][7].

HY-143704S

5-Aminosalicylic acid-13C6 hydrochloride
5-Aminosalicylic acid-13C6 hydrochloride?(Mesalamine-13C6 hydrochloride; 5-ASA-13C6 hydrochloride; Mesalazine-13C6 hydrochloride) is the 13C labeled 5-Aminosalicylic Acidhydrochloride. 5-Aminosalicylic acid-13C6 hydrochloride?acts as a PPARγ agonist, and also inhibits p21-activated kinase 1 (PAK1) and NF-κB .

Cat. No.	Product Name		Classification

HY-107737

1,2-DLPC 1 Publications Verification 1,2-Dilauroyl-sn-glycero-3-phosphocholine		Phospholipids
1,2-DLPC (1,2-Dilauroyl-sn-glycero-3-phosphocholine) is a ligand for LRH-1 agonists. 1,2-DLPC is a phospholipid used in the synthesis of liposomes. 1,2-DLPC enhances fat breakdown and apoptosis in fat cells through a TNFα-dependent pathway, while also inhibiting palmitate-induced insulin resistance through PPARα-mediated inflammation in muscle cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PPAR Agonist

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products